HomeProductsBioactive CompoundsMAPK/ERK PathwayRafDabrafenib
Chemical structure of CAS 1195765-45-7

Dabrafenib

CAS No.1195765-45-7
MDL No.N/A
MFC23H20F3N5O2S2
MW519.60
InChI KeyBFSMGDJOXZAERB-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Dabrafenib is an organofluorine antineoplastic agent, used as its mesylate salt in the treatment of metastatic melanoma. It functions as a B-Raf inhibitor, an antineoplastic agent, and an anticoronaviral agent. It is a sulfonamide, a member of 1,3-thiazoles, and an aminopyrimidine.

CAS No.1195765-45-7
Product NameDabrafenib
Health HazardHealth Hazard
Environmental HazardEnvironmental Hazard
Signal Word:Warning
HCode:H361-H373-H400-H410-H411
PCode:P203-P260-P273-P280-P318-P319-P391-P405-P501

Related Articles

Studies related to this compound and its mechanism of action

Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy.

Toxicology and applied pharmacology • Vol. 434 • 2022
PMID: 34780725DOI: 10.1016/j.taap.2021.115797

Combined SRPK and AKT pharmacological inhibition is synergistic in T-cell acute lymphoblastic leukemia cells.

Toxicology in vitro : an international journal published in association with BIBRA • Vol. 65 • 2020
PMID: 31962201DOI: 10.1016/j.tiv.2020.104777

Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy.

Nature communications • Vol. 9, Issue 1 • 2018
PMID: 29950559PMC: PMC6021375DOI: 10.1038/s41467-018-04664-0

Antiseptic effects of dabrafenib on TGFBIp-induced septic responses.

Chemico-biological interactions • Vol. 278 • 2017
PMID: 29042256DOI: 10.1016/j.cbi.2017.10.016

Documentation

Similar Products